Risk stratifications and outcomes of hormone receptor‐positive/human epidermal growth factor receptor 2 negative breast cancer prognostic tests CanAssist Breast (CAB) and Oncotype DX (ODX) were compared in a cohort of 109 patients who had previously taken the ODX test. This evidence concerns the gene ERBB2 and breast carcinoma.